Credit Suisse analyst Judah Frommer lowered the firm’s price target on Candel Therapeutics to $7 from $8 and keeps an Outperform rating on the shares. Candel reported Q4 results, highlighting recent company progress and reiterating existing catalyst timelines, and updated Phase 2 data for CAN-2409 in NSCLC is expected in 3Q23, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CADL:
- Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
- Candel Therapeutics expects cash to fund operating plan into 2Q24
- Candel Therapeutics announces anticipated 2023 milestones
- Candel Therapeutics reports Q4 EPS (18c), consensus (31c)
- Candel Therapeutics, Inc. (CADL) Q4 Earnings Cheat Sheet
